BACKGROUND: It has been proposed that lithium may be clinically effective due to its actions on the phosphoinositol second messenger system (PI-cycle). Studies have also suggested that untreated manic patients may have raised myo-inositol and phosphomonoester (PME) concentrations and also that unmedicated euthymic bipolar patients may have lowered PME concentrations. The objective of the present study was to test the hypothesis that chronic treatment with either lithium or sodium valproate in patients with bipolar mood disorder leads to a normalization in the activity of the PI-cycle. METHODS: This study had two parts each with different MRS methodology. The first part compared healthy controls (n = 19) with euthymic bipolar patients who were taking either lithium (n = 16) or sodium valproate (n = 11) using both (1)H-MRS and (31)P-MRS. In the second part we examined a separate group of euthymic bipolar disorder patients taking sodium valproate (n = 9) and compared these with age and sex-matched healthy controls (n = 11) using (1)H-MRS. RESULTS: Both studies showed that there were no differences in either myo-inositol or phosphomonoester (PME) concentrations between controls and patients taking either medication. CONCLUSIONS: These findings examine two key components of the PI-cycle in treated euthymic bipolar (myo-inositol and PME concentrations). The results from this study are consistent with the suggestion that chronic treatment with either lithium or sodium valproate in bipolar patients may normalize PI-cycle functioning. Copyright 2002 John Wiley & Sons, Ltd.
BACKGROUND: It has been proposed that lithium may be clinically effective due to its actions on the phosphoinositol second messenger system (PI-cycle). Studies have also suggested that untreated manicpatients may have raised myo-inositol and phosphomonoester (PME) concentrations and also that unmedicated euthymic bipolarpatients may have lowered PME concentrations. The objective of the present study was to test the hypothesis that chronic treatment with either lithium or sodium valproate in patients with bipolar mood disorder leads to a normalization in the activity of the PI-cycle. METHODS: This study had two parts each with different MRS methodology. The first part compared healthy controls (n = 19) with euthymic bipolarpatients who were taking either lithium (n = 16) or sodium valproate (n = 11) using both (1)H-MRS and (31)P-MRS. In the second part we examined a separate group of euthymic bipolar disorderpatients taking sodium valproate (n = 9) and compared these with age and sex-matched healthy controls (n = 11) using (1)H-MRS. RESULTS: Both studies showed that there were no differences in either myo-inositol or phosphomonoester (PME) concentrations between controls and patients taking either medication. CONCLUSIONS: These findings examine two key components of the PI-cycle in treated euthymic bipolar (myo-inositol and PME concentrations). The results from this study are consistent with the suggestion that chronic treatment with either lithium or sodium valproate in bipolarpatients may normalize PI-cycle functioning. Copyright 2002 John Wiley & Sons, Ltd.
Authors: Marquis P Vawter; Abdul Rezzak Hamzeh; Edgar Muradyan; Olivier Civelli; Geoffrey W Abbott; Amal Alachkar Journal: Mol Neuropsychiatry Date: 2019-08-08
Authors: Nina Vanessa Kraguljac; Meredith Reid; David White; Rebecca Jones; Jan den Hollander; Deborah Lowman; Adrienne Carol Lahti Journal: Psychiatry Res Date: 2012-09-13 Impact factor: 3.222
Authors: Mani N Pavuluri; Alessandra M Passarotti; Jacklynn M Fitzgerald; Ezra Wegbreit; John A Sweeney Journal: J Am Acad Child Adolesc Psychiatry Date: 2011-12-23 Impact factor: 8.829
Authors: Manpreet K Singh; Daniel Spielman; Allison Libby; Elizabeth Adams; Tenah Acquaye; Meghan Howe; Ryan Kelley; Allan Reiss; Kiki D Chang Journal: Bipolar Disord Date: 2011-03 Impact factor: 6.744
Authors: Nick C Patel; Melissa P DelBello; Kim M Cecil; Caleb M Adler; Holly S Bryan; Kevin E Stanford; Stephen M Strakowski Journal: Biol Psychiatry Date: 2006-11-01 Impact factor: 13.382
Authors: B J Eickholt; G J Towers; W J Ryves; D Eikel; K Adley; L M J Ylinen; N H Chadborn; A J Harwood; H Nau; R S B Williams Journal: Mol Pharmacol Date: 2005-02-01 Impact factor: 4.436
Authors: Daniel P Dickstein; Kenneth E Towbin; Jan Willem Van Der Veen; Brendan A Rich; Melissa A Brotman; Lisa Knopf; Laura Onelio; Daniel S Pine; Ellen Leibenluft Journal: J Child Adolesc Psychopharmacol Date: 2009-02 Impact factor: 2.576
Authors: Jun Xu; Ulrike Dydak; Jaroslaw Harezlak; Jonathan Nixon; Mario Dzemidzic; Abigail D Gunn; Harish S Karne; Amit Anand Journal: Psychiatry Res Date: 2013-06-27 Impact factor: 3.222